06 July 2012 | News | By BioSpectrum Bureau
Stemtech enters into exclusive deal with Marinova
Singapore: Stemtech International, a pioneer in stem cell nutrition, has signed an exclusive business deal with Marinova, an Australian biotech firm, to supply Fucoidan (seaweed extracts) for use in Stemtech's new generation stem cell enhancer SE2. Marinova is the only global supplier of Fucoidan that is certified organic and prepared with a proprietary cold water procedure that uses no solvents, so its methods meet Stemtech's exacting standards for product ingredients.
Stemtech President and CEO, Mr Ray C Carter, Jr, orchestrated the multi-million dollar deal with Marinova in anticipation of the explosion in the supplement market for supporting stem cell physiology that is on the horizon. "The emerging field of stem cell nutrition has the real potential to eclipse the massive antioxidant supplement business," said Mr Carter in a NUTRAIngredients interview, following the announcement of the deal with Marinova.
Marinova's business development manager Mr Kevin Krail told NUTRAIngredients, "Our proprietary species of Fucoidan has been clinically shown to increase the number of adult stem cells in circulation and help them migrate and adhere where they are needed." He noted that the deal with Stemtech will establish Marinova as the world leader in the production of Fucoidan.
In clinical trials, Fucoidan has been shown not only to enhance the release of adult stem cells from the bone marrow but also to enhance the sticky receptor CXCR4 on the stem cells themselves, significantly increasing their effectiveness as part of the body's natural renewal system. In SE2, a clinical study shows that Marinova's Fucoidan works in concert with a patented concentrate of Aphanizomenon flos-aquae (AFA), the herb Polygonum multiflorum and Cordyceps sinensisto deliver a powerful formula that supports cell and tissue renewal. The formula for SE2 has been developed using solid science, which has been the consistent practice with Stemtech's product development since the company was founded. "We decided to partner exclusively with Stemtech," Krail said, "as they have done quality clinical research on their proprietary ingredients and now with our proprietary Fucoidan ingredient."
Stemtech's Chief Science Officer Mr Christian Drapeau has led ongoing product research and has published a number of studies on done with Stemtech's products, including the 2007 article in the prestigious journal Cardiovascular Revascularization Medicine and a 2010 article about increased muscle recovery that appeared in Cell Cycle. "Our research shows consistently that there is a direct link between health and the number of circulating stem cells," Mr Drapeau said, adding, "The development of many degenerative diseases has been linked to a reduced number of naturally circulating stem cells, when compared to a healthy population. Therefore, increasing the number of circulating stem cells supports the day-to-day process of tissue repair and helps the body to maintain health."
Stemtech markets its patented products exclusively through over 100,000 independent distributors in 22 countries and has already generated sales in excess of $200 million since the company's founding in 2005.